BioArctic's Promising Step: Next Phases of Exidavnemab Study Begin After Safety Review
BioArctic to Proceed with Next Cohorts for Exidavnemab
BioArctic AB has announced a significant milestone in its clinical development of exidavnemab, a promising treatment for neurodegenerative diseases including Parkinson's disease and Multiple System Atrophy (MSA). Following an interim safety review of the Phase 2a study, known as EXIST, the results indicated that the drug is safe and well-tolerated. As a result, the company will now initiate the next cohorts, which will evaluate higher doses of exidavnemab compared to a placebo.
Overview of the Phase 2a Study
The EXIST study is designed to assess the safety and pharmacokinetic profile of exidavnemab. The initial cohort focused on a lower dosage of the drug, and the positive results have paved the way for expanding the study to include two additional cohorts that will administer higher doses. This advancement marks an important step in BioArctic's mission to develop treatments that can modify the course of debilitating brain diseases.